PolyPidPYPD
PYPD
About: PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Employees: 61
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
48% more capital invested
Capital invested by funds: $6.9M [Q1] → $10.2M (+$3.31M) [Q2]
15% more funds holding
Funds holding: 13 [Q1] → 15 (+2) [Q2]
3.41% more ownership
Funds ownership: 24.97% [Q1] → 28.38% (+3.41%) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
161%
upside
Avg. target
$12.25
255%
upside
High target
$14
306%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Chase Knickerbocker | 277%upside $13 | Buy Maintained | 14 Aug 2025 |
HC Wainwright & Co. Brandon Folkes | 277%upside $13 | Buy Reiterated | 13 Aug 2025 |
Roth Capital Boobalan Pachaiyappan | 161%upside $9 | Buy Maintained | 18 Jun 2025 |
JMP Securities Roy Buchanan | 306%upside $14 | Market Outperform Maintained | 17 Jun 2025 |
Financial journalist opinion
Based on 4 articles about PYPD published over the past 30 days
Neutral
Seeking Alpha
1 week ago
PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Dikla Czaczkes Akselbrad - CEO & Director Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer—US Conference Call Participants Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Douglas Royal Buchanan - Citizens JMP Securities, LLC, Research Division Yehuda Leibler - Unidentified Company Operator Greetings, and welcome to PolyPid's Second Quarter 2025 Conference Call.
Neutral
GlobeNewsWire
1 week ago
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI
Neutral
GlobeNewsWire
1 week ago
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
Dr. Tweezer-Zaks Transitions from the Company's Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline Dr. Tweezer-Zaks Transitions from the Company's Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline
Neutral
GlobeNewsWire
3 weeks ago
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Neutral
GlobeNewsWire
1 month ago
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The GLP-1 delivery platform expands PolyPid's product portfolio beyond the recently successful Phase 3 D-PLEX100, demonstrating versatility of the Company's proprietary drug delivery platforms in multiple major therapeutic areas.
Neutral
GlobeNewsWire
2 months ago
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million. The Company anticipates that with this additional funding, PolyPid's runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀.
Neutral
GlobeNewsWire
2 months ago
PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention
PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future
Neutral
GlobeNewsWire
2 months ago
PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention
PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future
Neutral
GlobeNewsWire
2 months ago
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery patients with large incisions.
Neutral
GlobeNewsWire
2 months ago
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
PETACH TIKVA, Israel, June 09, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced positive topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 for the prevention of SSIs in patients undergoing abdominal colorectal surgery with large incisions, which has received Fast Track designation from the FDA.
Charts implemented using Lightweight Charts™